Nano-X (NNOX) — Mapping the commercial footprint and what it means for investors

Nano‑X Imaging sells and licenses its Nanox.ARC digital X‑ray systems through a network of exclusive regional distributors, commercial partners and clinical collaborators; the company monetizes via system sales, recurring service agreements and AI imaging partnerships that extend clinical workflows. Recent disclosures show a deliberate channel-led expansion across the U.S., Europe and Latin America that materially shifts commercial risk from in‑house sales to partner execution. Learn more about the dataset behind this coverage at https://nullexposure.com/.

Why the partner map matters for valuation

Nano‑X is still a development‑stage medical devices company with negative gross profit and operating losses (Revenue TTM $13.0M; Gross profit TTM -$12.8M; EBITDA negative), so scaling depends on distribution partners to deliver unit placements, service revenue and clinical validation. The distribution strategy accelerates reach but concentrates counterparty risk: exclusive and regional agreements create dependency on the commercial discipline and balance‑sheet strength of local partners.

Who Nano‑X is working with — relationship snapshots

Below are concise, source‑backed descriptions of every partner listed in Nanox’s customer results.

Alphea France SARL — Nanox signed a distribution agreement in France with Alphea France SARL, part of the Altair Group, positioning Alphea to market and support Nanox.ARC in French healthcare channels, according to Nanox’s Q3 2025 earnings call (reported March 7, 2026).

Cedars‑Sinai — Nanox referenced Cedars‑Sinai as a prominent collaborator within its expanding clinical and network activities, per the Q3 2025 earnings call transcript (March 2026).

3DR Labs / 3DR Labs, LLC — Nanox formed a commercial partnership enabling 3DR Labs to offer Nanox.AI’s FDA‑cleared imaging solutions to its network of providers; this was announced in a Nov. 18, 2025 press release and reiterated in the Q3 2025 call.

Covera Health — Nanox expanded an existing agreement with Covera Health to integrate imaging/AI workflows, as discussed on the Q3 2025 earnings call (March 2026).

X‑ray (Czech distributor) — Nanox entered a distribution agreement with a leading Czech medical imaging distributor referred to as X‑ray to introduce Nanox.ARC to Czech healthcare providers, according to the Q3 2025 earnings call.

Radiology Oncology Systems — Nanox announced a U.S. distribution agreement with Radiology Oncology Systems to expand Nanox.ARC adoption nationwide; reported in GlobeNewswire and MarketScreener in April 2026.

Intec SRL (Argentina) — Nanox granted Intec SRL exclusive distribution rights in Argentina covering marketing, installation and support for Nanox.ARC, per a GlobeNewswire release dated Feb. 19, 2026.

VASO / Vaso Corporation — Nanox described a technical and go‑to‑market synergy involving VHC IT / Vaso Corporation to integrate its FDA‑cleared imaging AI into customer environments, referenced on the Q3 2025 earnings call transcript.

Imperial Imaging Technology LLC — Nanox signed Imperial Imaging Technology to distribute Nanox.ARC across several southeastern U.S. states (Georgia, Alabama, Tennessee, Carolinas, northern Florida), announced via GlobeNewswire and industry feeds in March 2026.

Elite Surgical Technologies — Nanox’s U.S. subsidiary signed Elite Surgical Technologies as a distributor to promote Nanox.ARC across targeted U.S. healthcare markets, per a GlobeNewswire release on April 1, 2026.

Digital X‑Ray Imaging Inc. — Nanox Impact Inc. appointed Digital X‑Ray Imaging to distribute Nanox.ARC across Arkansas, as announced in April 2026 industry releases.

Adriamed d.o.o. Beograd (Adriamed) — Nanox named Adriamed as its exclusive partner for Serbia, Montenegro and Bosnia & Herzegovina, responsible for full commercial and support activities, per a Jan. 14, 2026 press release.

Howard Technology Solutions — Nanox signed a commercial agreement with Howard Technology Solutions to deploy 300 Nanox.ARC systems in the U.S. over three years (60 units in year one highlighted), detailed in company press material and reported by The Globe and Mail and GlobeNewswire in April 2026.

Meir Medical Center — Nanox announced a collaboration to deploy Nanox.ARC for an orthopedic imaging clinical study at Meir Medical Center (part of Clalit), in an April 2026 GlobeNewswire release.

Hospital Privé Jacques Cartier MASSY — Nanox is partnering with Olympe Imagerie and Hospital Privé Jacques Cartier MASSY to demonstrate Nanox.ARC for lung cancer screening workflows in Paris hospitals, reported by MuggleHead in March 2026.

Olympe Imagerie — Nanox announced collaboration with Olympe Imagerie on Nov. 14 (referenced in coverage of clinical deployments), as reported in March 2026 news coverage.

Integrity Medical Service, Inc. — Nanox signed a distribution agreement with Integrity Medical Service to deploy Nanox.ARC systems in Colorado and adjacent markets; this was included in GlobeNewswire and other April 2026 releases.

Integrity Imaging — Nanox referenced Integrity Imaging as a U.S. imaging‑channel partner with established relationships across imaging centers, cited in the Q4 2025 earnings call transcript summary available through earnings coverage in May 2026.

Elite Surgical — Listed separately in press summaries, Elite Surgical serves surgical and specialty environments and is cited across Nanox press releases in April 2026.

Regional Sports Medicine in Orthopedic Group — Nanox reported its first U.S. orthopedic practice customer as Regional Sports Medicine in Orthopedic Group, per the Q4 2025 earnings call transcript coverage.

(Each item above is drawn from Nanox earnings call transcripts and company press releases published across March–May 2026, including GlobeNewswire, Marketscreener, InsiderMonkey and industry outlets.)

What these relationships imply about Nano‑X’s operating model

• Channel‑first contracting posture. Nanox systematically executes exclusive and regional distribution agreements and framework deals rather than building a global direct salesforce; this shifts commercialization risk to partners and accelerates market access.
• Geographic concentration and diversification at once. The partner list shows concentrated efforts in the U.S. (multiple regional distributors and a 300‑unit Howard framework) paired with targeted exclusives in Latin America and Europe—an intentional mix to scale placements quickly.
• Criticality of partners to revenue maturity. With negative gross profit and small TTM revenue relative to market cap, partners are operationally critical: unit deployments, service contracts and clinical studies run through these third parties.
• Early commercial maturity. The company remains development‑stage with early commercial footholds and heavy reliance on partner rollout execution to generate the recurring revenue profile investors prize.

Investment implications — an executive checklist

• Upside: Rapid channel wins (Howard Tech, multiple U.S. distributors, exclusive Argentina and Balkan partners) reduce time‑to‑revenue and enable scale if partners execute and collectable service revenue follows unit placements.
• Downside: Partner credit risk, inconsistent execution across regions, and the company’s current negative gross profit create sequencing risk for margin improvement and free cash flow.
• Catalysts to watch: Quarterly announcements quantifying installations, recurring service revenue, and the first material revenue contribution from the Howard 300‑unit framework will materially de‑risk the thesis.
• Red flags: Delays in partner rollouts, terminations or payment disputes would directly impair revenue forecasts given the channel‑dependent model.

If you evaluate partner execution as pivotal to Nanox’s path to profitability, the current disclosures give a clear dossier of counterparties to model against operational scenarios. For a deeper read on partner evidence and source documents, visit https://nullexposure.com/.

Bottom line

Nano‑X has transitioned from product development toward a distributed commercial strategy built on exclusive regional partners and targeted clinical collaborations. That strategy materially accelerates potential scale but transfers execution risk to third parties; the next investor inflection point is concrete installation and recurring revenue metrics tied to these partners.